U.S. Orders 105 Million More Pfizer Shots for Fall Booster Campaign
Both Pfizer and Moderna have reported positive results with updated vaccines that target the omicron variant
Two Doses of BNT162b2 Moderately Effective for 5- to 11-Year-Olds
Moderate effectiveness against documented infection and symptomatic COVID-19 for those vaccinated on or after Nov. 23, 2021
NHS Privatization Tied to Increase in Treatable Mortality
Annual increase of 1 percent of outsourcing to the private for-profit sector linked to annual increase of 0.38 percent in treatable mortality
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
ACIP Recommends COVID-19 Vaccines for Children Aged ≥6 Months
ACIP interim recommendations presented for Moderna, Pfizer-BioNTech mRNA vaccines for children aged 6 months to 5 years
U.S. Begins Targeted Vaccine Rollout Against Monkeypox
HHS is rapidly expanding access to hundreds of thousands of doses of the Jynneos vaccine
FDA Panel Supports Rollout of Tweaked Booster Shots From Moderna, Pfizer This Fall
Advisory panel approval speeds the process by which FDA regulators will push for updated booster formulations
PrEP Stigma High Among U.S. Male Couples
Additionally, men underestimate effectiveness of PrEP
JCAHO Standards Not Always Supported by High-Quality Evidence
Of 20 actionable standards from The Joint Commission, six completely supported by references, six partly supported
SARS-CoV-2-Linked Hospitalization, ED Encounters Rare After Paxlovid
<1 percent of patients to whom Paxlovid was dispensed for mild-to-moderate COVID-19 had hospitalization or ED encounter
